BIP
CRMD icon

Brandes Investment Partners’s CorMedix CRMD Stock Holding History

Brandes Investment Partners’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-17,000
Closed -$43K – 142
2017
Q4 		$43K Buy
+17,000
New +$48.8K ﹤0.01% 157

Other funds holding CRMD

EM
Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SC
Spinnaker Capital Boston, Massachusetts $1.08M AUM 45.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
KWM
Kingsview Wealth Management Grants Pass, Oregon $7.33B AUM 16.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PD
Planning Directions Glen Mills, Pennsylvania $198M AUM 11.06% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Brandes Investment Partners's CRMD Position: Q1 2018 in Review

Brandes Investment Partners sold out of CorMedix (CRMD) in Q1 2018, closing a stake of 17,000 shares — an estimated $43K sold.

Brandes Investment Partners first reported a position in CRMD in Q4 2017 and held it in 1 quarter. The position peaked at $43K in Q4 2017. 35 funds tracked by Wall St. Rank hold CRMD as of Q1 2018.

  • Brandes Investment Partners reported no remaining CorMedix position as of Q1 2018 after selling out during the quarter.
  • Brandes Investment Partners sold 17,000 CorMedix shares in Q1 2018, an estimated $43K.
  • Brandes Investment Partners first reported a position in CorMedix in Q4 2017 and held it in 1 quarter.
  • Brandes Investment Partners's CorMedix position peaked at $43K in Q4 2017.
  • 35 funds tracked by Wall St. Rank held CorMedix as of Q1 2018.

Based on Brandes Investment Partners's 13F filing for Q1 2018, filed 15 May 2018.